Maze Therapeutics, Inc. (MAZE)
22.52
-0.92
(-3.92%)
USD |
NASDAQ |
Sep 18, 16:00
22.61
+0.09
(+0.40%)
Pre-Market: 20:00
Maze Therapeutics Total Liabilities (Quarterly) : 78.50M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 78.50M |
| March 31, 2026 | 78.01M |
| December 31, 2025 | 42.16M |
| September 30, 2025 | 42.62M |
| June 30, 2025 | 41.28M |
| Date | Value |
|---|---|
| March 31, 2025 | 40.77M |
| December 31, 2024 | 43.64M |
| September 30, 2024 | 93.11M |
| March 31, 2024 | |
| December 31, 2023 | 61.45M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 896.90M |
| Corcept Therapeutics, Inc. | 182.93M |
| Veru, Inc. | 8.651M |
| Johnson & Johnson | 116.09B |
| Eli Lilly & Co. | 108.40B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 531.62M |
| Shareholders Equity (Quarterly) | 453.12M |
| Debt to Equity Ratio | 0.1333 |
| Current Ratio | 18.31 |
| Net Debt Paydown Yield | -0.42% |